In keeping with its aim of becoming a next generation leader in biopharma, Bristol-Myers Squibb has agreed to sell its over the counter (OTC) assets in Asia (excluding China and Japan) and its Indonesian unit to Taisho Pharmaceutical Co of Japan for US$310 M.